Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- BCVA in EDTRS values
研究概览
简要总结
The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.
详细描述
To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •History of macular or chorioretinal inflammation
- •Lens / corneal opacities
研究组 & 干预措施
1
1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
干预措施: subthreshold micropulselaser (Device)
1
1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
干预措施: bevacizumab (Drug)
2
initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
干预措施: subthreshold micropulselaser (Device)
结局指标
主要结局
BCVA in EDTRS values
时间窗: 24 months
次要结局
- OCT, leakage in FA, defects in satic perimetry(24 months)
研究者
Michael Koss
PI
Johann Wolfgang Goethe University Hospital